title: Disease modification and other trials in systemic sclerosis have come a long way, but have to go further.
authors.affiliation: St. Joseph's Health Care London, University of Western Ontario, London, Ontario, Canada. janet.pope@sjhc.london.on.ca
authors.forename: Janet E
authors.initials: JE
authors.lastname: Pope
authors.forename: Dinesh
authors.initials: D
authors.lastname: Khanna
authors.forename: Sindhu R
authors.initials: SR
authors.lastname: Johnson
authors.forename: Phil
authors.initials: P
authors.lastname: Clements
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012595:Scleroderma, Systemic / Q000188:drug therapy*
chemical_list: D018501:Antirheumatic Agents